BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38321542)

  • 1. Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer.
    Rönnlund C; Sifakis EG; Schagerholm C; Yang Q; Karlsson E; Chen X; Foukakis T; Weidler J; Bates M; Fredriksson I; Robertson S; Hartman J
    Breast Cancer Res; 2024 Feb; 26(1):24. PubMed ID: 38321542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
    Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
    PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.
    Stocker A; Hilbers ML; Gauthier C; Grogg J; Kullak-Ublick GA; Seifert B; Varga Z; Trojan A
    PLoS One; 2016; 11(7):e0159176. PubMed ID: 27463363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results.
    Seo J; Koh J; Lee DW; Kim J; Ryu HS; Lee KH; Kim TY; Im SA
    Breast Cancer Res; 2023 Dec; 25(1):154. PubMed ID: 38098054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
    Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
    JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.
    Xu QQ; Pan B; Wang CJ; Zhou YD; Mao F; Lin Y; Guan JH; Shen SJ; Zhang XH; Xu YL; Zhong Y; Wang XJ; Zhang YN; Sun Q
    Oncotarget; 2016 Sep; 7(39):63571-63582. PubMed ID: 27566580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
    Takada M; Higuchi T; Tozuka K; Takei H; Haruta M; Watanabe J; Kasai F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Ogawa S; Kaneko Y
    BMC Cancer; 2013 May; 13():241. PubMed ID: 23679233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes.
    Xuan Q; Ji H; Tao X; Xu Y; Zhang Q
    Breast Cancer Res Treat; 2015 Apr; 150(3):581-8. PubMed ID: 25762478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.
    Prat A; Pascual T; De Angelis C; Gutierrez C; Llombart-Cussac A; Wang T; Cortés J; Rexer B; Paré L; Forero A; Wolff AC; Morales S; Adamo B; Brasó-Maristany F; Vidal M; Veeraraghavan J; Krop I; Galván P; Pavlick AC; Bermejo B; Izquierdo M; Rodrik-Outmezguine V; Reis-Filho JS; Hilsenbeck SG; Oliveira M; Dieci MV; Griguolo G; Fasani R; Nuciforo P; Parker JS; Conte P; Schiff R; Guarneri V; Osborne CK; Rimawi MF
    J Natl Cancer Inst; 2020 Jan; 112(1):46-54. PubMed ID: 31037288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer.
    Choi JH; Jeon CW; Kim YO; Jung S
    Medicine (Baltimore); 2020 Nov; 99(46):e23053. PubMed ID: 33181670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
    Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
    JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.
    Lee HJ; Seo AN; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
    Br J Cancer; 2015 Jan; 112(1):103-11. PubMed ID: 25349977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
    Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P
    ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.
    Calhoun BC; Portier B; Wang Z; Minca EC; Budd GT; Lanigan C; Tubbs RR; Morrison LE
    BMC Cancer; 2016 Aug; 16(1):695. PubMed ID: 27576528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial.
    Guarneri V; Bras-Maristany F; Dieci MV; Griguolo G; Par L; Mar Ín-Aguilera M; Miglietta F; Bottosso M; Giorgi CA; Blasco P; Castillo O; Galv N P; Vivancos A; Villagrasa P; Parker JS; Perou CM; Conte P; Prat A
    EBioMedicine; 2022 Nov; 85():104320. PubMed ID: 36374768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep learning identifies morphological features in breast cancer predictive of cancer ERBB2 status and trastuzumab treatment efficacy.
    Bychkov D; Linder N; Tiulpin A; Kücükel H; Lundin M; Nordling S; Sihto H; Isola J; Lehtimäki T; Kellokumpu-Lehtinen PL; von Smitten K; Joensuu H; Lundin J
    Sci Rep; 2021 Feb; 11(1):4037. PubMed ID: 33597560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact.
    Page DB; Wen H; Brogi E; Dure D; Ross D; Spinelli KJ; Patil S; Norton L; Hudis C; McArthur HL
    Breast Cancer Res Treat; 2018 Jan; 167(2):547-554. PubMed ID: 28986743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
    Fountzilas G; Dafni U; Bobos M; Kotoula V; Batistatou A; Xanthakis I; Papadimitriou C; Kostopoulos I; Koletsa T; Tsolaki E; Televantou D; Timotheadou E; Koutras A; Klouvas G; Samantas E; Pisanidis N; Karanikiotis C; Sfakianaki I; Pavlidis N; Gogas H; Linardou H; Kalogeras KT; Pectasides D; Dimopoulos MA
    BMC Cancer; 2013 Mar; 13():163. PubMed ID: 23537287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
    Tan RSYC; Ong WS; Lee KH; Lim AH; Park S; Park YH; Lin CH; Lu YS; Ono M; Ueno T; Naito Y; Onishi T; Lim GH; Tan SM; Lee HB; Ryu HS; Han W; Tan VKM; Wong FY; Im SA; Tan PH; Chan JY; Yap YS
    BMC Med; 2022 Mar; 20(1):105. PubMed ID: 35296300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.